Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with new Facility in India
News Oct 25, 2007
Thermo Fisher Scientific Inc. has announced that it has broken ground on a new $17 million (USD) facility in Ahmadabad, India, to support growing demand for biopharma services in that country.
The facility will focus on packaging, global distribution and logistics management of tightly regulated pharmaceutical samples to patients participating in clinical trials across the globe. It will complement existing clinical services operations in the U.S., Europe and Asia. The company expects to open the new 100,000-square-foot facility by spring of 2008, and add approximately 100 employees in the first year of operation.
"Large pharmaceutical companies are focusing more and more on India for their future clinical research and development programs," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific.
"They are looking to outsource their clinical trials management to partners who know how to work within changing regional and global clinical trial regulations. By expanding our capacity to serve the needs of both multi- national and local pharmaceutical companies, we will be able to bring a higher level of technology, quality and expertise to facilitate clinical trials," said Dekkers.
Thermo Fisher Scientific has taken significant steps over the past few years to increase its overall presence in India, adding sales and manufacturing facilities to support growing markets, including biopharma services and biospecimen storage, life sciences research and industrial processing.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE